MD05

Scil Technology GmbH · Phase 2 active Small molecule

At a glance

Generic name	MD05
Sponsor	Scil Technology GmbH
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Open Label Extension for GLYX13-C-202, NCT01684163 (PHASE2)
Pilot Study on Safety and Efficacy of MD05 in Comparison With Beta-TCP in Patients Undergoing Sinus Floor Augmentation (PHASE2)
Pilot Study on MD05 in Comparison With Open Flap Debridement in Patients Undergoing Periodontal Surgery (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MD05 CI brief — competitive landscape report
MD05 updates RSS · CI watch RSS
Scil Technology GmbH portfolio CI